Glycomine, a leading biotechnology company based in San Francisco, has achieved a notable milestone by raising $115 million in funding for their pioneering project, GLM101. This development is particularly significant in an economic environment where securing substantial capital remains
Ivan Kairatov is a distinguished figure in the biopharma industry, renowned for his expertise in tech and innovation within the field. With a robust background in research and development, Ivan has substantially influenced advancements in cellular therapies and drug development. Today, we delve
Verve Therapeutics has announced a significant advancement in genetic medicine as their investigational drug VERVE-102 receives Fast Track designation from the U.S. Food and Drug Administration (FDA). This approval marks a crucial step in the development of treatments for hyperlipidemia and
A research study published in Nature has revealed a groundbreaking link between the shingles vaccine and a significant reduction in the risk of developing dementia among seniors. By leveraging data from the 2013 implementation of a shingles immunization program in Wales, researchers have identified
Ivan Kairatov is a recognized authority in the biopharma sector, with an extensive background in technological advancements and R&D. In this interview, Ivan shares his insights on the new FDA-approved treatment for IgA nephropathy (IgAN), shedding light on its significance in treating this rare
Glioblastoma, one of the most aggressive and treatment-resistant forms of brain cancer, presents a dire prognosis even with current standard treatment regimens including surgery, radiation, and the chemotherapy drug temozolomide (TMZ). However, a groundbreaking study published in Volume 16 of
